When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CNAT - Conatus completes enrollment in mid-stage study of emricasan in NASH cirrhosis
Conatus Pharmaceuticals
Conatus Pharmaceuticals (NASDAQ:CNAT) has completed enrollment in its Phase 2b clinical trial, ENCORE-LF, evaluating lead drug emricasan in patients with stable decompensated NASH cirrhosis.
More news on: Conatus Pharmaceuticals, Healthcare stocks news,